TN2013000434A1 - Novel imidazole derivatives useful for the treatment of arthritis - Google Patents
Novel imidazole derivatives useful for the treatment of arthritisInfo
- Publication number
- TN2013000434A1 TN2013000434A1 TNP2013000434A TN2013000434A TN2013000434A1 TN 2013000434 A1 TN2013000434 A1 TN 2013000434A1 TN P2013000434 A TNP2013000434 A TN P2013000434A TN 2013000434 A TN2013000434 A TN 2013000434A TN 2013000434 A1 TN2013000434 A1 TN 2013000434A1
- Authority
- TN
- Tunisia
- Prior art keywords
- arthritis
- treatment
- imidazole derivatives
- derivatives useful
- novel imidazole
- Prior art date
Links
- 206010003246 arthritis Diseases 0.000 title 1
- 150000002460 imidazoles Chemical class 0.000 title 1
- 229940079865 intestinal antiinfectives imidazole derivative Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 150000003839 salts Chemical class 0.000 abstract 2
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/88—Nitrogen atoms, e.g. allantoin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Physical Education & Sports Medicine (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161490222P | 2011-05-26 | 2011-05-26 | |
| PCT/US2012/037200 WO2012161965A1 (fr) | 2011-05-26 | 2012-05-10 | Nouveaux dérivés d'imidazole utiles pour le traitement de l'arthrite |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TN2013000434A1 true TN2013000434A1 (en) | 2015-03-30 |
Family
ID=46148987
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TNP2013000434A TN2013000434A1 (en) | 2011-05-26 | 2013-10-24 | Novel imidazole derivatives useful for the treatment of arthritis |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US8648200B2 (fr) |
| EP (1) | EP2714679A1 (fr) |
| JP (1) | JP2014518886A (fr) |
| KR (1) | KR20130143138A (fr) |
| CN (1) | CN103562200A (fr) |
| AR (1) | AR086254A1 (fr) |
| AU (1) | AU2012259234A1 (fr) |
| BR (1) | BR112013029692A2 (fr) |
| CA (1) | CA2836240A1 (fr) |
| CO (1) | CO6811858A2 (fr) |
| CR (1) | CR20130534A (fr) |
| DO (1) | DOP2013000276A (fr) |
| EA (1) | EA201391568A1 (fr) |
| EC (1) | ECSP13013047A (fr) |
| IL (1) | IL229318A0 (fr) |
| MA (1) | MA35128B1 (fr) |
| MX (1) | MX2013013859A (fr) |
| PH (1) | PH12013502435A1 (fr) |
| SG (1) | SG195020A1 (fr) |
| TN (1) | TN2013000434A1 (fr) |
| TW (1) | TW201311658A (fr) |
| WO (1) | WO2012161965A1 (fr) |
| ZA (1) | ZA201308609B (fr) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8871947B2 (en) | 2013-02-04 | 2014-10-28 | KingChem LLC | Preparation of alkyl 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid ester |
| CN103467379A (zh) * | 2013-08-23 | 2013-12-25 | 江苏恒安化工有限公司 | 3-三氟甲基-1-甲基吡唑-4-甲酸的制备方法 |
| CN103601675B (zh) * | 2013-10-08 | 2015-10-28 | 南京复兴生物科技有限公司 | 一种5-氨甲基烟酸的制备方法 |
| CN103483250B (zh) * | 2013-10-08 | 2015-07-22 | 南京复兴生物科技有限公司 | 一种5-氨甲基烟酸的制备方法 |
| US9139507B2 (en) | 2013-12-09 | 2015-09-22 | KingChem LLC. | Process for the preparation of alkyl 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylate and its analogs |
| TWI651310B (zh) | 2014-02-20 | 2019-02-21 | 日商日本煙草產業股份有限公司 | 三化合物及其醫藥用途 |
| WO2015143240A2 (fr) * | 2014-03-19 | 2015-09-24 | Curza Global, Llc | Compositions et procédés comprenant des 2- (acylamino) imidazoles |
| KR20160134865A (ko) | 2014-04-14 | 2016-11-23 | 샹하이 헨그루이 파마수티컬 컴퍼니 리미티드 | 아미드 유도체 및 이의 약제학적으로 허용되는 염, 이의 제조방법 및 이의 의학적 적용 |
| EP4046991A1 (fr) * | 2015-08-17 | 2022-08-24 | Japan Tobacco Inc. | Composés d'hydroxytriazine et leur utilisation pharmaceutique |
| EP3601232B1 (fr) | 2017-03-31 | 2022-11-23 | Curza Global LLC | Compositions et procédés comprenant des 2-aminoimidazoles substitués |
| CN109293567A (zh) * | 2018-11-23 | 2019-02-01 | 上海睿腾医药科技有限公司 | 一种5-溴-2-甲基烟酸乙酯的合成方法 |
| WO2020249799A1 (fr) | 2019-06-14 | 2020-12-17 | Janssen Pharmaceutica Nv | Carbamates de pyridine et leur utilisation en tant que modulateurs du récepteur glun2b |
| UA129329C2 (uk) | 2019-06-25 | 2025-03-19 | Гіліад Сайєнсіз, Інк. | ЗЛИТІ БІЛКИ FLT3L-Fc |
| CN118178645A (zh) | 2019-10-18 | 2024-06-14 | 四十七公司 | 用于治疗骨髓增生异常综合征和急性髓系白血病的联合疗法 |
| MY209360A (en) | 2019-10-31 | 2025-07-03 | Forty Seven Llc | Anti-cd47 and anti-cd20 based treatment of blood cancer |
| TWI778443B (zh) | 2019-11-12 | 2022-09-21 | 美商基利科學股份有限公司 | Mcl1抑制劑 |
| CN110845426A (zh) * | 2019-11-29 | 2020-02-28 | 都创(上海)医药科技有限公司 | 一种2-氯-5-氰基嘧啶化合物制备方法 |
| SI4081305T1 (sl) | 2019-12-24 | 2025-03-31 | Carna Biosciences, Inc. | Spojine, ki modulirajo diacilglicerol kinazo |
| CR20220396A (es) | 2020-02-14 | 2022-11-14 | Jounce Therapeutics Inc | Anticuerpos y proteínas de fusión que se unen a ccr8 y usos de estos |
| WO2021222522A1 (fr) | 2020-05-01 | 2021-11-04 | Gilead Sciences, Inc. | Composés de 2,4-dioxopyrimidine inhibant cd73 |
| TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症 |
| TW202313094A (zh) | 2021-05-18 | 2023-04-01 | 美商基利科學股份有限公司 | 使用ＦＬＴ３Ｌ—Ｆｃ融合蛋白之方法 |
| WO2022271659A1 (fr) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Composés modulant les diacylglycérol kinases |
| CA3222595A1 (fr) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Composes de modulation de la diacylglycerol kinase |
| MX2023014762A (es) | 2021-06-23 | 2024-01-15 | Gilead Sciences Inc | Compuestos moduladores de diacilglicerol quinasa. |
| KR20240023629A (ko) | 2021-06-23 | 2024-02-22 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
| JP2024539252A (ja) | 2021-10-28 | 2024-10-28 | ギリアード サイエンシーズ， インコーポレイテッド | ピリジジン－３（２ｈ）－オン誘導体 |
| KR20240097895A (ko) | 2021-10-29 | 2024-06-27 | 길리애드 사이언시즈, 인코포레이티드 | Cd73 화합물 |
| US20240124412A1 (en) | 2021-12-22 | 2024-04-18 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| WO2023122615A1 (fr) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Agents de dégradation des doigts de zinc de la famille ikaros et leurs utilisations |
| IL313831A (en) | 2021-12-28 | 2024-08-01 | Nippon Shinyaku Co Ltd | Indazole compound and pharmaceutical preparation |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| CR20240386A (es) | 2022-03-17 | 2024-10-24 | Gilead Sciences Inc | Degradadores de dedos de zinc de la familia ikaros y usos de estos |
| AU2023240346A1 (en) | 2022-03-24 | 2024-09-19 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
| TWI876305B (zh) | 2022-04-05 | 2025-03-11 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
| CA3249472A1 (fr) | 2022-04-21 | 2023-10-26 | Gilead Sciences, Inc. | Composés modulateurs de virus du sarcome de rat de kirsten g12d |
| CN119384415A (zh) | 2022-07-01 | 2025-01-28 | 吉利德科学公司 | Cd73化合物 |
| US20240091351A1 (en) | 2022-09-21 | 2024-03-21 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY |
| EP4638436A1 (fr) | 2022-12-22 | 2025-10-29 | Gilead Sciences, Inc. | Inhibiteurs de prmt5 et leurs utilisations |
| EP4695260A1 (fr) | 2023-04-11 | 2026-02-18 | Gilead Sciences, Inc. | Composés modulateurs de kras |
| EP4698533A1 (fr) | 2023-04-21 | 2026-02-25 | Gilead Sciences, Inc. | Inhibiteurs de prmt5 et leurs utilisations |
| WO2025006720A1 (fr) | 2023-06-30 | 2025-01-02 | Gilead Sciences, Inc. | Composés modulateurs de kras |
| US20250100998A1 (en) | 2023-07-26 | 2025-03-27 | Gilead Sciences, Inc. | Parp7 inhibitors |
| US20250066328A1 (en) | 2023-07-26 | 2025-02-27 | Gilead Sciences, Inc. | Parp7 inhibitors |
| WO2025054530A1 (fr) | 2023-09-08 | 2025-03-13 | Gilead Sciences, Inc. | Dérivés polycycliques contenant une pyrimidine utilisés comme composés de modulation de kras g12d |
| US20250101042A1 (en) | 2023-09-08 | 2025-03-27 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| US20250154172A1 (en) | 2023-11-03 | 2025-05-15 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2025137640A1 (fr) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Inhibiteurs azaspiro de wrn |
| WO2025245003A1 (fr) | 2024-05-21 | 2025-11-27 | Gilead Sciences, Inc. | Inhibiteurs de prmt5 et leurs utilisations |
| CN119161260A (zh) * | 2024-06-26 | 2024-12-20 | 安徽大学 | 一种1-（2-氨基-4-氟-5-甲氧基苯基）-1-丙酮的合成方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1802605A1 (fr) * | 2004-10-15 | 2007-07-04 | Amgen, Inc | Derives d'imidazole utilises en tant que ligands du recepteur de la vanilloide |
| US8084466B2 (en) * | 2007-12-18 | 2011-12-27 | Janssen Pharmaceutica Nv | Bicyclic heteroaryl-substituted imidazoles as modulators of the histamine H4 receptor |
| WO2009103778A1 (fr) | 2008-02-19 | 2009-08-27 | Novasaid Ab | Composés et procédés |
| UY32470A (es) | 2009-03-05 | 2010-10-29 | Boehringer Ingelheim Int | Derivados de 2-{2-cloro-5-[(sustituido) metil]fenilamino} -1-metil]fenilamino}-1-metilbencimidazol-5-carboxamidas-n-(sustituidas) y sus sales fisiológicamente aceptables, composiciones conteniéndolos y aplicaciones |
| WO2010127152A2 (fr) * | 2009-04-29 | 2010-11-04 | Irm Llc | Composés et compositions comme inhibiteurs de la prostaglandine e synthase-1 microsomale |
| JP5579862B2 (ja) * | 2009-10-23 | 2014-08-27 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ミクロソームプロスタグランジンｅ２シンターゼ−１のインヒビター |
| AR084174A1 (es) * | 2010-12-21 | 2013-04-24 | Lilly Co Eli | Compuestos de imidazol-2-benzamida utiles para el tratamiento de osteoartritis y una composicion farmaceutica |
-
2012
- 2012-05-03 AR ARP120101556A patent/AR086254A1/es not_active Application Discontinuation
- 2012-05-04 TW TW101116086A patent/TW201311658A/zh unknown
- 2012-05-10 EA EA201391568A patent/EA201391568A1/ru unknown
- 2012-05-10 SG SG2013085154A patent/SG195020A1/en unknown
- 2012-05-10 CN CN201280025230.2A patent/CN103562200A/zh active Pending
- 2012-05-10 WO PCT/US2012/037200 patent/WO2012161965A1/fr not_active Ceased
- 2012-05-10 BR BR112013029692A patent/BR112013029692A2/pt not_active IP Right Cessation
- 2012-05-10 US US13/468,122 patent/US8648200B2/en not_active Expired - Fee Related
- 2012-05-10 CA CA2836240A patent/CA2836240A1/fr not_active Abandoned
- 2012-05-10 JP JP2014512861A patent/JP2014518886A/ja active Pending
- 2012-05-10 EP EP12723323.7A patent/EP2714679A1/fr not_active Withdrawn
- 2012-05-10 PH PH1/2013/502435A patent/PH12013502435A1/en unknown
- 2012-05-10 AU AU2012259234A patent/AU2012259234A1/en not_active Abandoned
- 2012-05-10 KR KR1020137030893A patent/KR20130143138A/ko not_active Ceased
- 2012-05-10 MX MX2013013859A patent/MX2013013859A/es unknown
-
2013
- 2013-10-18 CR CR20130534A patent/CR20130534A/es unknown
- 2013-10-24 TN TNP2013000434A patent/TN2013000434A1/fr unknown
- 2013-11-07 IL IL229318A patent/IL229318A0/en unknown
- 2013-11-15 ZA ZA2013/08609A patent/ZA201308609B/en unknown
- 2013-11-15 MA MA36452A patent/MA35128B1/fr unknown
- 2013-11-22 DO DO2013000276A patent/DOP2013000276A/es unknown
- 2013-11-22 CO CO13275568A patent/CO6811858A2/es not_active Application Discontinuation
- 2013-11-25 EC ECSP13013047 patent/ECSP13013047A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20130143138A (ko) | 2013-12-30 |
| TW201311658A (zh) | 2013-03-16 |
| DOP2013000276A (es) | 2014-03-31 |
| ECSP13013047A (es) | 2014-01-31 |
| US20120302608A1 (en) | 2012-11-29 |
| US8648200B2 (en) | 2014-02-11 |
| CA2836240A1 (fr) | 2012-11-29 |
| AR086254A1 (es) | 2013-11-27 |
| SG195020A1 (en) | 2013-12-30 |
| AU2012259234A1 (en) | 2013-11-14 |
| JP2014518886A (ja) | 2014-08-07 |
| PH12013502435A1 (en) | 2014-01-13 |
| MA35128B1 (fr) | 2014-05-02 |
| EP2714679A1 (fr) | 2014-04-09 |
| WO2012161965A1 (fr) | 2012-11-29 |
| EA201391568A1 (ru) | 2014-04-30 |
| IL229318A0 (en) | 2014-01-30 |
| CN103562200A (zh) | 2014-02-05 |
| MX2013013859A (es) | 2014-05-28 |
| BR112013029692A2 (pt) | 2017-01-17 |
| CR20130534A (es) | 2014-03-12 |
| ZA201308609B (en) | 2015-05-27 |
| CO6811858A2 (es) | 2013-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TN2013000434A1 (en) | Novel imidazole derivatives useful for the treatment of arthritis | |
| TN2014000058A1 (en) | A Novel 1,2,3,4-Tetrahydroquinoline Derivative Useful for the Treatment of Diabetes | |
| EA201590879A1 (ru) | Арилконденсированные и гетероарилконденсированные лактамы | |
| PH12015501585A1 (en) | Manufacturing process for pyrimidine derivatives | |
| TN2015000034A1 (en) | Derivatives of azaindazole or diazaindazole type for treating pain | |
| MY165087A (en) | Neprilysin inhibitors | |
| IN2014KN00948A (fr) | ||
| TN2012000248A1 (en) | Novel spiropiperidine compounds | |
| TN2012000152A1 (en) | Spiropiperidine compounds and pharmaceutical use thereof for treating diabetes | |
| MX2015008975A (es) | Analogos de tiadiazol y metodos para el tratamiento de afecciones relacionadas con deficiencia del gen de supervivencia de las neuronas motoras (smn). | |
| MX2013011329A (es) | Combinaciones de compuestos inhibidores de akt y erlotinib y metodos de uso. | |
| MX2013008431A (es) | Antagonista del receptor de mineralocorticoides. | |
| PH12013500301A1 (en) | Oxadiazole inhibitors of leukotriene production | |
| PH12014501711A1 (en) | Benzyl sulfonamide derivatives useful as mogat-2 inhibitors | |
| IN2014CN04449A (fr) | ||
| PH12015500111A1 (en) | Difluorolactam compositions for ep4-mediated osteo related diseases and conditions | |
| PH12014501712A1 (en) | Novel morpholinyl derivatives useful as mogat-2-inhibitors | |
| NZ700356A (en) | Pyrazole compounds as sglt1 inhibitors | |
| MD20160111A2 (ro) | Derivaţi diheterociclici legaţi de cicloalchil | |
| TN2014000135A1 (en) | Substituted pyrazole analogues as rar antagonists | |
| MX2015007460A (es) | Agentes para el tratamiento del dolor y usos de los mismos. | |
| NZ724424A (en) | Pyrimidine derivatives for the treatment of bacterial diseases | |
| MX2013002446A (es) | Derivados de tetrahidropirrolopirazina sustituidos. | |
| TN2014000307A1 (en) | Novel morpholinyl derivatives useful as mogat-2 inhibitors | |
| TN2013000094A1 (en) | Manufacturing process for pyrimidine derivatives |